Komori
Share Issuance and Disposal4583Chiome Bioscience Inc.Pharmaceuticals

Notice Regarding the Monthly Exercise Status of the 23rd Stock Acquisition Rights (with Exercise Price Adjustment Clause)

In May 2026, 1,883,900 shares' worth of the 23rd Stock Acquisition Rights were exercised, reducing the balance of unexercised rights from 72,045 to 53,206 (representing 5,320,600 shares). The exercise price ranged from ¥92.0 to ¥77.3 during the month.

Worth reading
27Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
1883900
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Monthly exercise status of stock acquisition rights with an exercise price adjustment clause

発行・処分する株式数

Number of shares delivered during the month: 1,883,900 shares (all newly issued shares; transferred treasury shares: 0 shares)

発行済株式総数

Exercise ratio during the month: 13.85% (ratio to the total number issued); exercise ratio subject to exercise restrictions: 2.77% (ratio of the number of shares delivered during the month to the number of listed shares outstanding as of the payment date for the issuance)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
Exercise prices during the month: ¥92.0, ¥87.4, ¥86.5, ¥85.6, ¥82.8, ¥81.0, ¥81.9 and ¥77.3. An exercise price adjustment clause applies. The lower limit of the adjustment is Not disclosed.
Number of Stock Acquisition Rights
Total number issued: Not disclosed. Number of unexercised rights outstanding at the end of the preceding month: 72,045. Number of unexercised rights outstanding at the end of the month: 53,206. Number of rights exercised during the month: 18,839.
Procedures under the Corporate Code of Conduct
The disclosure describes compliance with exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments and Other Transactions.
Most recent equity financing
Timing 15 December 2025 / Type Issuance of the 23rd Series Stock Acquisition Rights (with Exercise Price Adjustment Clause) / Amount Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalMonthly exercise status of stock acquisition rights with an exercise price adjustment clause
Number of shares to be issued or disposed ofNumber of shares delivered during the month: 1,883,900 shares (all newly issued shares; transferred treasury shares: 0 shares)
Dilution RateExercise ratio during the month: 13.85% (ratio to the total number issued); exercise ratio subject to exercise restrictions: 2.77% (ratio of the number of shares delivered during the month to the number of listed shares outstanding as of the payment date for the issuance)
Exercise priceExercise prices during the month: ¥92.0, ¥87.4, ¥86.5, ¥85.6, ¥82.8, ¥81.0, ¥81.9 and ¥77.3. An exercise price adjustment clause applies. The lower limit of the adjustment is Not disclosed.
Number of Stock Acquisition RightsTotal number issued: Not disclosed. Number of unexercised rights outstanding at the end of the preceding month: 72,045. Number of unexercised rights outstanding at the end of the month: 53,206. Number of rights exercised during the month: 18,839.
Procedures under the Corporate Code of ConductThe disclosure describes compliance with exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments and Other Transactions.
Most recent equity financingTiming 15 December 2025 / Type Issuance of the 23rd Series Stock Acquisition Rights (with Exercise Price Adjustment Clause) / Amount Not disclosed
Items this document does not state (21)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyTotal number of issued sharesBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To report the monthly exercise status of the 23rd Stock Acquisition Rights in May 2026.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Monthly Exercise Status of the 23rd Stock Acquisition Rights (with Exercise Price Adjustment Clause) | Chiome Bioscience Inc. (4583) timely disclosure | Komori